SIGLEC6 Human
Sf9, Baculovirus cells.
Sialic Acid Binding Ig Like Lectin 6, Obesity-Binding Protein 1, CD33 Antigen-Like 1, CDW327, CD33L1, CD33L, OBBP1, Sialic Acid Binding Ig-Like Lectin 6, Sialic Acid-Binding Ig-Like Lectin 6, CD327 Antigen, Siglec-6, CD33L2, OB-BP1, CD327, SIGLEC6.
Greater than 90.0% as determined by SDS-PAGE.
Description
SIGLEC6 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 563 amino acids (27-347a.a.) and having a molecular mass of 62.6kDa (Molecular size on SDS-PAGE will appear at approximately 70-100kDa). SIGLEC6 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Sialic Acid Binding Ig Like Lectin 6, Obesity-Binding Protein 1, CD33 Antigen-Like 1, CDW327, CD33L1, CD33L, OBBP1, Sialic Acid Binding Ig-Like Lectin 6, Sialic Acid-Binding Ig-Like Lectin 6, CD327 Antigen, Siglec-6, CD33L2, OB-BP1, CD327, SIGLEC6.
Sf9, Baculovirus cells.
ADLQERRFQL EGPESLTVQE GLCVLVPCRL PTTLPASYYG YGYWFLEGAD VPVATNDPDE EVQEETRGRF HLLWDPRRKN CSLSIRDARR RDNAAYFFRL KSKWMKYGYT SSKLSVRVMA LTHRPNISIP GTLESGHPSN LTCSVPWVCE QGTPPIFSWM SAAPTSLGPR TTQSSVLTIT PRPQDHSTNL TCQVTFPGAG VTMERTIQLN VSYAPQKVAI SIFQGNSAAF KILQNTSSLP VLEGQALRLL CDADGNPPAH LSWFQGFPAL NATPISNTGV LELPQVGSAE EGDFTCRAQH PLGSLQISLS LFVHWKPEGR AGGVLEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGKHHH HHH.
Product Science Overview
Sialic Acid Binding Ig Like Lectin 6 (Siglec-6) is a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. These are cell surface proteins predominantly expressed on immune cells and play a crucial role in modulating immune responses. Siglec-6, in particular, has garnered attention due to its potential implications in immunotherapy and its unique expression profile.
Siglec-6 is a protein-coding gene associated with the innate immune system and antigen processing pathways . It is characterized by its ability to bind sialic acids, which are a type of sugar molecule found on the surface of cells. This binding capability allows Siglec-6 to interact with other cells and modulate immune responses.
Siglec-6 is not widely expressed in healthy tissues, making it an attractive target for therapeutic interventions. Its expression has been noted in certain cancers, including chronic lymphocytic leukemia (CLL), where it serves as a novel target for immunotherapy . The absence of Siglec-6 in most healthy cells and tissues reduces the risk of off-target effects, which is a significant advantage in developing targeted therapies.
Recent studies have highlighted the potential of Siglec-6 as a target for cancer immunotherapy. For instance, patient-derived antibodies targeting Siglec-6 have shown promise in recruiting T-cells to eliminate cancer cells . These antibodies can be engineered into bispecific antibodies that bind both Siglec-6 and CD3, enhancing their therapeutic efficacy .
Ongoing research aims to further understand the role of Siglec-6 in the immune system and its potential as a therapeutic target. Studies have demonstrated that targeting Siglec-6 can activate T-cells and kill Siglec-6 positive target cells, providing a foundation for developing new cancer treatments .
